This application requests Cancer Center Support Grant funding for the Holden Comprehensive Cancer Center (HCCC) at the University of Iowa. This is the second CCSG competitive renewal for the HCCC. The HCCC functions administratively as a matrix Cancer Center with 189 Center members from six colleges and 36 departments across the University. It leverages the resources and expertise provided by the medical center and across the University to support and strengthen transdisciplinary cancer research. The HCCC has extensive support from both the institution and via private support. The members of the HCCC have $74.2 million in total annual cancer-related, peer-reviewed, external research support. Of this, over $20.4 million comes from the NCI. The HCCC is organized into six research programs that are each designed to be translational in nature. Together they encompass a broad spectrum of strength in basic laboratory, clinical and population research. These programs are 1) Cancer Immunology &Immunotherapy, 2) Cancer Signaling and Experimental Therapeutics, 3) Free Radical Cancer Biology, 4) Tumor Imaging, 5).Cancer Epidemiology, and 6) Cancer Genomics and Cell Growth. In addition to the Administrative Core, the HCCC supports eleven shared resources including: 1) DNA, 2) Gene Transfer Vector, 3) Radiation and Free Radical Research, 4) Flow Cytometry, 5) Central Microscopy Research Facility, 6) Small Animal Imaging, 7) Tissue Procurement 8) Bioinformatics, 9) Population Research, 10) Biostatistics, and 11) Clinical Trials Support. Through these programs and cores, and an effective organizational structure, the HCCC enhances interactions, supports collaborations, and sets the direction of future cancer research activities at the HCCC.
The Cancer Center Support Grant supports the infrastructure of the Holden Comprehensive Cancer Center. This infrastructure allows the Center to foster excellence in research across a broad spectrum of scientific areas relevant to cancer, and translate those advances to the clinic with the goal of reducing the morbidity and mortality of cancer.
|Mahauad-Fernandez, Wadie D; Naushad, Wasifa; Panzner, Tyler D et al. (2018) BST-2 promotes survival in circulation and pulmonary metastatic seeding of breast cancer cells. Sci Rep 8:17608|
|Lodge, Martin A; Leal, Jeffrey P; Rahmim, Arman et al. (2018) Measuring PET Spatial Resolution Using a Cylinder Phantom Positioned at an Oblique Angle. J Nucl Med 59:1768-1775|
|Swami, Umang; Ma, Deqin; Zhang, Jun (2018) Response to Erlotinib in a Patient with Compound EGFR L747S and Exon 19 Deletion. J Thorac Oncol 13:e129-e130|
|Heer, Collin D; Davis, Andrew B; Riffe, David B et al. (2018) Superoxide Dismutase Mimetic GC4419 Enhances the Oxidation of Pharmacological Ascorbate and Its Anticancer Effects in an H?O?-Dependent Manner. Antioxidants (Basel) 7:|
|Kondratick, Christine M; Litman, Jacob M; Shaffer, Kurt V et al. (2018) Crystal structures of PCNA mutant proteins defective in gene silencing suggest a novel interaction site on the front face of the PCNA ring. PLoS One 13:e0193333|
|Panel, Nicolas; Villa, Francesco; Fuentes, Ernesto J et al. (2018) Accurate PDZ/Peptide Binding Specificity with Additive and Polarizable Free Energy Simulations. Biophys J 114:1091-1102|
|Field, R William (2018) Radon: A Leading Environmental Cause of Lung Cancer. Am Fam Physician 98:280-282|
|Morrison, Emma A; Bowerman, Samuel; Sylvers, Kelli L et al. (2018) The conformation of the histone H3 tail inhibits association of the BPTF PHD finger with the nucleosome. Elife 7:|
|Liu, Yiwei; Dong, Zhengwei; Jiang, Tao et al. (2018) Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. Clin Lung Cancer 19:e421-e430|
|Gounder, Mrinal M; Mahoney, Michelle R; Van Tine, Brian A et al. (2018) Sorafenib for Advanced and Refractory Desmoid Tumors. N Engl J Med 379:2417-2428|
Showing the most recent 10 out of 1080 publications